FDA clears AstraZeneca, Merck drug to treat some genetic breast cancers early
Bio Pharma Dive
MARCH 14, 2022
Lynparza is the first drug targeting BRCA mutations to be approved for use in early breast cancer, a decision that could lead to more genetic testing.
Let's personalize your content